Clinical Trials Logo

Advanced Endometrial Cancer clinical trials

View clinical trials related to Advanced Endometrial Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05481645 Recruiting - Clinical trials for Advanced Endometrial Cancer

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Start date: August 22, 2022
Phase: Phase 2
Study type: Interventional

This study plans to enroll 69 subjects of endometrial cancer and 5-10 subjects of sarcoma of uterus. The experimental set is divided into lead-in trial and formal trial. The lead-in trial includes 9 subjects to observe the safety of the combination and determine the dosage of anlotinib dihydrochloride capsules before the formal phase. The formal trial includes 60 subjects of endometrial cancer and 5-10 subjects of sarcoma of uterus. The purpose is to evaluate efficacy and safety of TQB2450 injection combined with chemotherapy ± anlotinib hydrochloride capsules for first-line treatment and maintenance treatment of patient with advanced endometrial cancer or sarcoma of uterus, and explore biomarkers related to efficacy, mechanism of action, safety and/or pathological mechanisms, the surgical conversion rate. ORR is the primary endpoint.

NCT ID: NCT05112991 Recruiting - Clinical trials for Advanced Endometrial Cancer

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Start date: March 4, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.

NCT ID: NCT04574284 Recruiting - Clinical trials for Advanced Endometrial Cancer

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Start date: September 29, 2020
Phase: Phase 2
Study type: Interventional

This is a study to evaluate the efficacy and safety of TQB2450 injection or combined with anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial cancer.